Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alcaftadine is a small molecule antihistamine used as an ophthalmic solution to prevent itching associated with allergic conjunctivitis. It acts primarily as a direct antagonist and inverse agonist at the histamine H1 receptor, but also exhibits activity at H2 and H4 receptors. Alcaftadine inhibits the release of histamine from mast cells, reduces eosinophil recruitment, and has anti-inflammatory effects in ocular tissues. It was approved for medical use in July 2010 and is available both as a prescription and over-the-counter medication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alcaftadine.